Skip to main
ANIK
ANIK logo

Anika Therapeutics (ANIK) Stock Forecast & Price Target

Anika Therapeutics (ANIK) Analyst Ratings

Based on 1 analyst ratings
Buy
Strong Buy 0%
Buy 100%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Anika Therapeutics has demonstrated strong revenue momentum, with its Integrity product line projected to achieve over 100% growth in revenue from 2024 to 2025, reflecting robust market demand. Additionally, the company reported a 13% increase in international osteoarthritis pain revenue in the first quarter, indicating solid performance in a key therapeutic area. Furthermore, the regenerative solutions segment has exhibited significant growth, recording a remarkable 41% increase in the recent quarter, largely attributed to the successful adoption of the Integrity patch.

Bears say

Anika Therapeutics reported a revenue of $28.2 million, reflecting an 8.2% decline compared to the same period last year when adjusted for recent divestitures, indicating potential challenges in maintaining growth. Furthermore, international revenue from osteoarthritis pain management decreased by 10% due to order timing and production yield issues, suggesting operational difficulties. Over the past 12-18 months, the company has faced a series of negative developments that have negatively impacted investor confidence, contributing to a detrimental outlook for the stock.

Anika Therapeutics (ANIK) has been analyzed by 1 analysts, with a consensus rating of Buy. 0% of analysts recommend a Strong Buy, 100% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Anika Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Anika Therapeutics (ANIK) Forecast

Analysts have given Anika Therapeutics (ANIK) a Buy based on their latest research and market trends.

According to 1 analysts, Anika Therapeutics (ANIK) has a Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Anika Therapeutics (ANIK)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.